Physician profile
Kay D Barney
NPI 1215003017
$6,464.21
in general payments reported to CMS, 2019-2025
36 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $1,049 · 2021: $1,229 · 2022: $889 · 2023: $585 · 2024: $532 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,267.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,695.69 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $740.71 | 2021-2025 | Ubrelvy |
| Axsome Therapeutics, INC. | $579.49 | 2022-2025 | Auvelity |
| Lilly USA, LLC | $489.24 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Mannkind Corporation | $461.82 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $345.78 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $279.30 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Novo Nordisk INC | $247.38 | 2019-2025 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $214.27 | 2021-2023 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $164.21 | 2025 | Zoryve |
| Neos Therapeutics, LP | $135.50 | 2019-2021 | |
| Shire North American Group INC | $99.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.44 | 2019-2021 | |
| Allergan, INC. | $85.11 | 2019-2020 | |
| Amgen INC. | $78.96 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $78.35 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $76.82 | 2020 | |
| Astellas Pharma US INC | $74.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $70.97 | 2020-2022 | |
| Abbott Laboratories | $69.28 | 2022-2025 | Freestyle Libre 3 |
| Corium, LLC | $57.67 | 2022-2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $44.05 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $35.92 | 2019-2020 | |
| Exact Sciences Corporation | $34.66 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $32.11 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.04 | 2019 | |
| Philips North America LLC | $19.86 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.14 | 2025 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $16.99 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.96 | 2022 | |
| Gilead Sciences, INC. | $16.15 | 2020 | |
| Adlon Therapeutics L.P. | $14.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.56 | 2020 | |
| Collegium Pharmaceutical, INC. | $12.42 | 2021 | |
| Vistapharm, INC. | $12.23 | 2021 | |
| Bausch Health US, LLC | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay Barney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.